Literature DB >> 8349789

Altered renal kallikrein and renin gene expression in nephrotic rats and modulation by converting enzyme inhibition.

F N Hutchison1, S K Webster, A A Jaffa.   

Abstract

Urinary kallikrein excretion (UKE) is decreased in rats with passive Heymann nephritis (PHN), but increases after converting enzyme inhibition (CEI). Although CEI potentiates bradykinin activity, neither the effect of CEI on kallikrein secretion nor the abnormal renal kallikrein metabolism in PHN has been examined previously. To determine the mechanism by which CEI increases UKE, normal rats and PHN received enalapril, 40 mg/kg per d orally for 4 d. UKE was 85% lower in PHN than in normals and increased in both groups after CEI, although UKE in PHN remained significantly less than in normals. Kallikrein mRNA was significantly lower in PHN compared to normals but not in PHN treated with CEI and did not change in normal rats. Renin mRNA was significantly lower in PHN, and was stimulated by CEI only in normals. Renal kallikrein and renin content were not different and were not altered by CEI. Both kallikrein and renin genes appear to be transcriptionally suppressed in rats with PHN and the depressed kallikrein mRNA levels can be reversed by CEI. The modest increase in UKE despite normalization of kallikrein mRNA after CEI suggests that there is also a posttranscriptional defect in synthesis and/or secretion of kallikrein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349789      PMCID: PMC294948          DOI: 10.1172/JCI116612

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Effect of glandular kallikrein on renin release in isolated rat glomeruli.

Authors:  W H Beierwaltes; J Prada; O A Carretero
Journal:  Hypertension       Date:  1985 Jan-Feb       Impact factor: 10.190

3.  Renal vasoconstrictive effect of kinins mediated by B1-kinin receptors.

Authors:  J A Guimarães; M A Vieira; M J Camargo; T Maack
Journal:  Eur J Pharmacol       Date:  1986-11-04       Impact factor: 4.432

4.  Urinary kallikrein in experimental renal disease.

Authors:  R J Glasser; A F Michael
Journal:  Lab Invest       Date:  1976-06       Impact factor: 5.662

Review 5.  Renal kallikrein-kinin system. Relation to renal function and blood pressure.

Authors:  R K Mayfield; H S Margolius
Journal:  Am J Nephrol       Date:  1983 Mar-Jun       Impact factor: 3.754

6.  Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin.

Authors:  J E Sealey; S A Atlas; J H Laragh; N B Oza; J W Ryan
Journal:  Nature       Date:  1978-09-14       Impact factor: 49.962

7.  Mechanism and significance of kinin formation in nephrotic syndrome.

Authors:  K Nakamura; M Kazama; M Morioka; C Tahara; T Abe
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

8.  Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.

Authors:  S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

9.  Altered blood pressure and renin responses to converting enzyme inhibition after aprotinin-induced kallikrein-kinin-system blockade.

Authors:  A Overlack; K O Stumpe; M Kühnert; I Heck
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

10.  A direct radioimmunoassay of rat urinary kallikrein and comparison with other measures of urinary kallikrein activity.

Authors:  K Shimamoto; H S Margolius; J Chao; A R Crosswell
Journal:  J Lab Clin Med       Date:  1979-07
View more
  1 in total

Review 1.  Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease.

Authors:  H S Margolius
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.